US20120077842A1 - Quinoline derivative-containing pharmaceutical composition - Google Patents

Quinoline derivative-containing pharmaceutical composition Download PDF

Info

Publication number
US20120077842A1
US20120077842A1 US13/322,961 US201013322961A US2012077842A1 US 20120077842 A1 US20120077842 A1 US 20120077842A1 US 201013322961 A US201013322961 A US 201013322961A US 2012077842 A1 US2012077842 A1 US 2012077842A1
Authority
US
United States
Prior art keywords
composition according
group
examples
hydrogen atom
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/322,961
Other languages
English (en)
Inventor
Masashi Bando
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20120077842(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Assigned to EISAI R&D MANAGEMENT CO., LTD. reassignment EISAI R&D MANAGEMENT CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BANDO, MASASHI
Publication of US20120077842A1 publication Critical patent/US20120077842A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Definitions

  • the present invention relates to a pharmaceutical composition comprising a quinoline derivative, useful as a medicament. More specifically, the present invention relates to a pharmaceutical composition improved in dissolution of a quinoline derivative or a pharmaceutically acceptable salt thereof or a solvate thereof.
  • a quinoline derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof has been known to have a potent angiogenesis inhibitory effect (Patent Literature 1) and a c-Kit kinase inhibitory effect (Patent Literature 2) and to be useful as a preventive or therapeutic agent against various tumors such as thyroid cancer, lung cancer, melanoma and pancreatic cancer, and as an metastatic inhibitor against these tumors:
  • R 1 is a hydrogen atom, a C 1-6 alkyl group or a C 3-8 cycloalkyl group
  • R 2 is a hydrogen atom or a methoxy group
  • the quinoline derivative (I) has been found to degrade under humidifying and warming storage conditions when formulated into a pharmaceutical composition.
  • the pharmaceutical composition absorbs moisture, dissolution of the quinoline derivative (I) from the pharmaceutical composition that is an active ingredient may delay because of gelation on the surface of the composition.
  • a pharmaceutical composition which includes the quinoline derivative (I), (1) a compound, a 5% (w/w) aqueous solution or suspension of which has a pH of 8 or more, and/or (2) silicic acid, salt thereof or solvate thereof has been developed (Patent Literature 3).
  • the present invention is aimed at providing a pharmaceutical composition that is excellent in dissolution of the quinoline derivative (I) that is maintained even after long term storage.
  • the present invention provides the following ⁇ 1> to ⁇ 12>.
  • a pharmaceutical composition comprising:
  • R 1 is a hydrogen atom, a C 1-6 alkyl group or a C 3-8 cycloalkyl group
  • R 2 represents a hydrogen atom or a methoxy group
  • composition according to [1], wherein the basic substance is a carbonate [3] The composition according to [2], wherein the salt is an alkaline earth metal salt [4] The composition according to [3], wherein the alkaline earth metal salt is a magnesium salt or a calcium salt. [5] The composition according to any one of [1] to [4], further comprising a disintegrating agent. [6] The composition according to [5], wherein the disintegrating agent is carmellose sodium, carmellose calcium, carboxymethyl starch sodium, croscarmellose sodium, low-substituted hydroxypropylcellulose or crospovidone.
  • composition according to any one of [1] to [10], wherein the pharmaceutically acceptable salt is hydrochloride, hydrobromide, p-toluenesulfonate, sulfate, methanesulfonate or ethanesulfonate.
  • the compound represented by the formula (I) is 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate.
  • the pharmaceutical composition of the present invention is excellent in dissolution of the quinoline derivative (I), which is a principal agent, and is also excellent in absorption into a living body.
  • the pharmaceutical composition is also a pharmaceutical composition that is maintained even after long term storage.
  • FIG. 1 shows the dissolution profiles of the compound A from the pharmaceutical compositions obtained in Examples 4 to 6 and Comparative Example 1.
  • FIG. 2 shows the dissolution profiles of the compound A from the pharmaceutical compositions obtained in Examples 7 to 9 and Comparative Example 2.
  • FIG. 3 shows the dissolution patterns of the compound A from the pharmaceutical compositions obtained in Examples 10 to 12 and Comparative Example 3.
  • FIG. 4 shows the dissolution profiles of the compound A from the pharmaceutical compositions obtained in Examples 13 to 15 and Comparative Example 4.
  • FIG. 5 shows the dissolution profiles of the compound A from the pharmaceutical compositions obtained in Examples 16 to 17 and Comparative Example 5.
  • FIG. 6 shows the dissolution profiles of the compound A from the pharmaceutical compositions obtained in Example 18 and Comparative Examples 7 to 8.
  • FIG. 7 shows the dissolution profiles of the compound A from the pharmaceutical compositions obtained in Example 19 and Comparative Examples 9 to 10.
  • the pharmaceutical composition of the present invention means a composition comprising the quinoline derivative (I) and a basic substance as essential ingredients.
  • a mixing ratio of the quinoline derivative (I) and the basic substance is, but is not limited to, normally 1:0.5 to 50, preferably 1:1 to 25, further preferably 1:2 to 12.5.
  • a mixing rate of the quinoline derivative (I) with respect to the total weight of the pharmaceutical composition (excluding a capsule shell) is normally 0.25 to 50 weight %, preferably 0.5 to 25 weight %, further preferably 1 to 12.5 weight %.
  • a mixing rate of the basic substance with respect to the total weight of the pharmaceutical composition is normally 1 to 60 weight %, preferably 5 to 50 weight %, further preferably 10 to 40 weight %. At least one basic substance of the present invention may be included in the pharmaceutical composition, or two or more basic substances may also be included.
  • a dosage form of the pharmaceutical composition specifically means a solid preparation such as granules, fine granules, tablets or capsules and so on. It is preferably fine granules, granules or capsules filled with fine granules or granules.
  • the quinoline derivative (I) is a compound disclosed in WO 2002/32872.
  • a preferable quinoline derivative (I) is a quinoline derivative or pharmacologically acceptable salt thereof or solvate thereof selected from the group consisting of 4-(3-fluoro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide, 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-methoxyethoxy)-6-quinolinecarboxamide, 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-(2-hydroxyethoxy)-6-quinolinecarboxamide, 4-(3-chloro-4-(cyclopropylamino
  • a more preferable quinoline derivative (I) is a quinoline derivative or pharmacologically acceptable salt thereof or solvate thereof selected from the group consisting of 4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, 4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide and N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarbox
  • a particularly preferable quinoline derivative (I) is 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or pharmacologically acceptable salt thereof or solvate thereof.
  • the pharmaceutically acceptable salt of the present invention means hydrochloride, hydrobromide, p-toluenesulfonate, sulfate, methanesulfonate or ethanesulfonate. It is preferably the methanesulfonate.
  • the solvate of the present invention means hydrate, dimethyl sulfoxide solvate or acetic acid solvate.
  • the quinoline derivative (I) is preferably a crystal of a salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, or a solvate thereof disclosed in WO 2005/063713.
  • a particularly preferred quinoline derivative (I) is the C Form crystal of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate.
  • the quinoline derivative (I) is useful as a preventive or therapeutic agent against various tumors and as a metastasis inhibitor against tumors.
  • the tumors against which the quinoline derivative (I) is effective include thyroid cancer, non-small-cell lung cancer, melanoma, laryngopharyngeal cancer, esophageal cancer, gastric cancer, colorectal cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, bladder cancer, breast cancer, uterine cancer, ovarian cancer, prostate cancer, testicular cancer, gastrointestinal stromal tumor, sarcoma, osteogenic sarcoma, angioma, malignant lymphoma, myeloid leukemia, neuroma and neuroglioma.
  • the basic substance of the present invention means a basic inorganic salt.
  • Such basic inorganic salts include beryllium carbonate, magnesium carbonate, calcium carbonate, strontium carbonate, barium carbonate, potassium carbonate, calcium hydrogenphosphate and titanium oxide. It is preferably an alkaline earth metal salt of carbonic acid, further preferably magnesium carbonate or calcium carbonate.
  • a disintegrating agent in the pharmaceutical composition of the present invention.
  • a disintegrating agent include corn starch, partially pregelatinized starch, hydroxypropyl starch, carmellose, carmellose sodium, carmellose calcium, carboxymethyl starch sodium, croscarmellose sodium, low-substituted hydroxypropylcellulose and crospovidone. It is preferably the croscarmellose sodium, the low-substituted hydroxypropylcellulose or the crospovidone.
  • the pharmaceutical composition of the present invention may be prepared by a known method such as a method described in the General Rules for Preparations in the Japanese Pharmacopoeia Fifteenth Edition.
  • the granule it is possible to add an excipient, a binder, a disintegrating agent, a solvent, or the like to the quinoline derivative (I) as needed, to perform agitation granulation, extruding granulation, tumbling granulation, fluidized-bed granulation, spray granulation, or the like, and to prepare it.
  • an atomizing agent containing the quinoline derivative (I) and an additive such as corn starch, microcrystalline cellulose, hydroxypropylcellulose, methylcellulose or polyvinylpyrrolidone while spraying water or a solution of a binder such as saccharose, hydroxypropylcellulose or hydroxypropylmethylcellulose on a core material such as a purified sucrose spherical granule, a lactose/crystalline cellulose spherical granule, a saccharose/starch spherical granule or a granular crystalline cellulose. It is also acceptable to perform sizing and milling as needed.
  • an excipient e.g., a binder, a disintegrating agent, a lubricant, an anti-oxidizing agent, a corrigent, a coloring agent, a flavoring agent, or the like
  • a required excipient may be added to the quinoline derivative (I) to directly compress the mixture into a tablet.
  • quinoline derivative (I) added/mixed with an excipient such as lactose, saccharose, glucose, starch, microcrystalline cellulose, powdered glycyrrhiza, mannitol, calcium phosphate or calcium sulfate, or with the granule.
  • an excipient such as lactose, saccharose, glucose, starch, microcrystalline cellulose, powdered glycyrrhiza, mannitol, calcium phosphate or calcium sulfate, or with the granule.
  • excipient examples include lactose, saccharose, glucose, fructose, starch, potato starch, corn starch, wheat starch, rice starch, crystalline cellulose, microcrystalline cellulose, powdered glycyrrhiza, mannitol, erythritol, maltitol, sorbitol, trehalose, silicic anhydride, calcium silicate, sodium hydrogencarbonate, calcium phosphate, anhydrous calcium phosphate and calcium sulfate.
  • binder examples include gelatin, starch, gum arabic, tragacanth, carboxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, methylcellulose, partially pregelatinized starch, pregelatinized starch, polyvinyl alcohol, sodium arginine, pullulan and glycerin.
  • disintegrating agent examples include corn starch, partially pregelatinized starch, hydroxypropyl starch, carmellose, carmellose sodium, carmellose calcium, carboxymethyl starch sodium, croscarmellose sodium, low-substituted hydroxypropylcellulose and crospovidone.
  • lubricant examples include magnesium stearate, stearic acid, calcium stearate, sodium stearyl fumarate, talc and macrogol.
  • anti-oxidizing agent examples include sodium ascorbate, L-cysteine, sodium sulfite, tocopherol and soybean lecithin.
  • corrigent examples include citric acid, ascorbic acid, tartaric acid, malic acid, aspartame, acesulfame potassium, thaumatin, saccharin sodium, dipotassium glycyrrhizinate, sodium glutamate, sodium 5′-inosinate and sodium 5′-guanylate.
  • coloring agent examples include titanium oxide, iron sesquioxide, iron sesquioxide yellow, cochineal, carmine, riboflavin, food yellow No. 5 and food blue No. 2.
  • flavoring agent examples include lemon oil, orange oil, menthol, peppermint oil, borneol and vanilla flavor.
  • the granules of which a moisture content was reduced to be less than 2% by further drying were sized using a screen mill (apparatus name: Power Mill P-04S, manufactured by Showa Giken KK) so that their granule diameters were less than 1 mm. Then, microcrystalline cellulose (trade name: Ceolus PH-102, Asahi Kasei Chemicals) and talc (trade name: Hi-Filler 17, Iwai Chemicals Company) were added to the sized granules according to the formulation proportions in Table 1, and the mixture was thoroughly mixed using a diffusion (tumbler-type) mixer (trade name: 10L/20L Exchange-type Tumbler Mixer, manufactured by Toyo Packing Corporation). Hard capsules size #4 were filled with 100 mg of the resultant granules to prepare capsules containing the compound A.
  • a diffusion (tumbler-type) mixer trade name: 10L/20L Exchange-type Tumbler Mixer, manufactured by Toyo Packing Corporation.
  • the compound A, precipitated calcium carbonate, low-substituted hydroxypropylcellulose, D-mannitol and talc were thoroughly mixed using a mortar and a pestle according to the formulation proportions in Table 2 and Table 3. Hard capsules size #3 were filled with 100 mg of the resultant mixtures to prepare capsules in Examples 4 to 9. Capsules in Comparative Examples 1 to 2, which contained no precipitated calcium carbonate, were also prepared by the same method.
  • the compound A magnesium carbonate (Kyowa Chemical Industry), low-substituted hydroxypropylcellulose, D-mannitol and talc were thoroughly mixed using a mortar and a pestle according to the formulation proportions in Table 4 and Table 5. Hard capsules size #3 were filled with 100 mg of the resultant mixtures to prepare capsules in Examples 10 to 15. Capsules in Comparative Examples 3 to 4, which contained no magnesium carbonate, were also prepared by the same method.
  • Purified water was added to the compound A, precipitated calcium carbonate or magnesium carbonate, hydroxypropylcellulose and croscarmellose sodium (trade name: Ac-Di-Sol, Asahi Kasei Chemicals) to perform granulation using a mortar and a pestle, followed by sizing of the dried granules so that their granule diameters were less than 1 mm. Then, microcrystalline cellulose (trade name: Ceolus PH-102, Asahi Kasei Chemicals), low-substituted hydroxypropylcellulose and talc (trade name: Hi-Filler 17, Iwai Chemicals Company) were added to the sized granules according to the formulation proportions in Table 6, and the mixture was mixed thoroughly.
  • microcrystalline cellulose trade name: Ceolus PH-102, Asahi Kasei Chemicals
  • talc trade name: Hi-Filler 17, Iwai Chemicals Company
  • Hard capsules size #4 were filled with 100 mg of the resultant mixtures to prepare capsules in Examples 16 to 17.
  • the capsules in Examples 16 to 17 and Comparative Example 6 were stored for 1 week in an open system under an environment at a temperature of 60° C. and a relative humidity of 75%, followed by determining the production of the degradants with high-performance liquid chromatography.
  • the capsule formulation in Comparative Example 6 in which neither calcium carbonate nor magnesium carbonate was mixed, an amount of the degradants was increased.
  • the capsules in Examples 16 to 17, in which calcium carbonate or magnesium carbonate was mixed no increase in amount of the degradants was observed (Table 8).
  • the pharmaceutical composition of the present invention is excellent in dissolution of the quinoline derivative and also in stability, and is therefore useful as a medicament for prevention or treatment of a tumor.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
US13/322,961 2009-08-19 2010-08-16 Quinoline derivative-containing pharmaceutical composition Abandoned US20120077842A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009190145 2009-08-19
JP2009-190145 2009-08-19
PCT/JP2010/063804 WO2011021597A1 (ja) 2009-08-19 2010-08-16 キノリン誘導体含有医薬組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/063804 A-371-Of-International WO2011021597A1 (ja) 2009-08-19 2010-08-16 キノリン誘導体含有医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/923,858 Continuation US20130296365A1 (en) 2009-08-19 2013-06-21 Quinoline derivative-containing pharmaceutical composition

Publications (1)

Publication Number Publication Date
US20120077842A1 true US20120077842A1 (en) 2012-03-29

Family

ID=43607048

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/322,961 Abandoned US20120077842A1 (en) 2009-08-19 2010-08-16 Quinoline derivative-containing pharmaceutical composition
US13/923,858 Abandoned US20130296365A1 (en) 2009-08-19 2013-06-21 Quinoline derivative-containing pharmaceutical composition
US17/228,025 Pending US20210228722A1 (en) 2009-08-19 2021-04-12 Quinoline derivative-containing pharmaceutical composition

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/923,858 Abandoned US20130296365A1 (en) 2009-08-19 2013-06-21 Quinoline derivative-containing pharmaceutical composition
US17/228,025 Pending US20210228722A1 (en) 2009-08-19 2021-04-12 Quinoline derivative-containing pharmaceutical composition

Country Status (33)

Country Link
US (3) US20120077842A1 (pl)
EP (1) EP2468281B1 (pl)
JP (1) JP5048871B2 (pl)
KR (1) KR101496395B1 (pl)
CN (1) CN102470133B (pl)
AU (1) AU2010285740C1 (pl)
BR (1) BR112012003592B8 (pl)
CA (1) CA2771403C (pl)
CL (1) CL2012000412A1 (pl)
CO (1) CO6440512A2 (pl)
CY (1) CY1117481T1 (pl)
DK (1) DK2468281T3 (pl)
ES (1) ES2564797T3 (pl)
HK (2) HK1167607A1 (pl)
HR (1) HRP20160283T1 (pl)
HU (1) HUE026957T2 (pl)
IL (1) IL217197A (pl)
MA (1) MA33581B1 (pl)
ME (1) ME02359B (pl)
MX (2) MX344927B (pl)
MY (1) MY162940A (pl)
NZ (1) NZ598291A (pl)
PE (1) PE20121030A1 (pl)
PL (1) PL2468281T3 (pl)
RS (1) RS54686B1 (pl)
RU (1) RU2548673C3 (pl)
SG (1) SG178009A1 (pl)
SI (1) SI2468281T1 (pl)
SM (1) SMT201600077B (pl)
TH (1) TH121482A (pl)
UA (1) UA105671C2 (pl)
WO (1) WO2011021597A1 (pl)
ZA (1) ZA201108697B (pl)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080214557A1 (en) * 2005-09-01 2008-09-04 Eisai R&D Management Co., Ltd. Method for preparation of pharmaceutical composition having improved disintegratability and pharmaceutical composition manufactured by same method
US20080214604A1 (en) * 2004-09-17 2008-09-04 Hisao Furitsu Medicinal Composition
US20090264464A1 (en) * 2006-08-28 2009-10-22 Eisai R & D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US20100048620A1 (en) * 2007-01-29 2010-02-25 Yuji Yamamoto Composition for treatment of undifferentiated gastric cancer
US20100092490A1 (en) * 2005-08-02 2010-04-15 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
US20100239688A1 (en) * 2007-11-09 2010-09-23 Yuji Yamamoto Combination of anti-angiogenic substance and anti-tumor platinum complex
US20110207756A1 (en) * 2006-05-18 2011-08-25 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
US8815241B2 (en) 2005-11-07 2014-08-26 Eisai R&D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
WO2016136745A1 (ja) 2015-02-25 2016-09-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
EP3384901A1 (en) * 2017-04-04 2018-10-10 Synthon B.V. Pharmaceutical composition comprising lenvatinib mesylate
US10259791B2 (en) 2014-08-28 2019-04-16 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
CN110404079A (zh) * 2018-04-27 2019-11-05 北京睿创康泰医药研究院有限公司 一种不含碳酸盐、低基因毒性杂质含量的喹啉衍生物或其盐的药物组合物
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
US11547705B2 (en) 2015-03-04 2023-01-10 Merck Sharp & Dohme Llc Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106139156B (zh) * 2014-11-14 2019-01-29 江苏恒瑞医药股份有限公司 一种含有喹啉衍生物或其盐的药物组合物
CN106075456A (zh) * 2015-04-27 2016-11-09 南京圣和药业股份有限公司 一种含乐伐替尼的药物组合物及其应用
MX2017014799A (es) * 2015-05-21 2023-02-23 Crystal Pharmatech Co Ltd Forma cristalina novedosa de mesilato de lenvatinib y procedimiento de preparacion de la misma.
WO2017028660A1 (zh) * 2015-08-17 2017-02-23 江苏恒瑞医药股份有限公司 一种含有喹啉衍生物或其盐的药物组合物
RU2606592C1 (ru) * 2015-10-07 2017-01-10 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция, содержащая кальциевую соль розувастатина (варианты)
CZ2016240A3 (cs) 2016-04-27 2017-11-08 Zentiva, K.S. Soli lenvatinibu
US10583133B2 (en) 2018-03-12 2020-03-10 Shilpa Medicare Limited Pharmaceutical compositions of lenvatinib
ES2970132T3 (es) * 2018-10-04 2024-05-27 Synthon Bv Composición farmacéutica que comprende besilato de lenvatinib
PT3632436T (pt) 2018-10-04 2022-07-22 Synthon Bv Composição farmacêutica compreendendo sais de lenvatinib
CN113087666B (zh) * 2020-01-09 2021-12-14 南京正大天晴制药有限公司 无定形喹啉甲酰胺衍生物的制备方法
CN113491695A (zh) * 2020-03-18 2021-10-12 上海博志研新药物技术有限公司 一种仑伐替尼药物组合物、其制备方法及应用
EP4147689A1 (en) 2021-09-13 2023-03-15 Lotus Pharmaceutical Co., Ltd. Lenvatinib formulation
CN114306271B (zh) * 2021-11-24 2023-04-07 石药集团中奇制药技术（石家庄）有限公司 一种仑伐替尼组合物
CN115671074B (zh) * 2022-11-15 2024-06-04 郑州德迈药业有限公司 一种甲磺酸仑伐替尼制剂及其制备方法
EP4424303A1 (en) 2023-02-28 2024-09-04 Stada Arzneimittel Ag Lenvatinib composition with improved bioavailability

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550483B2 (en) * 2005-06-23 2009-06-23 Eisai R&D Management Co., Ltd. Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same
US20090304694A1 (en) * 2006-01-27 2009-12-10 Amgen Inc. Ang2 and Vegf Inhibitor Combinations
US20110158983A1 (en) * 2008-03-05 2011-06-30 Newell Bascomb Compositions and methods for mucositis and oncology therapies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1458148A (en) * 1974-04-19 1976-12-08 Wyeth John & Brother Ltd Carbocyclic-fused ring quinoline derivatives
US5009894A (en) * 1988-03-07 1991-04-23 Baker Cummins Pharmaceuticals, Inc. Arrangement for and method of administering a pharmaceutical preparation
KR100600550B1 (ko) * 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
AU2003273000A1 (en) * 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
EP1556356B1 (en) * 2002-10-21 2006-05-31 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as crth2 antagonists
EP1604665B1 (en) 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
RS54033B1 (en) * 2003-12-25 2015-10-30 Eisai R&D Management Co. Ltd. CRYSTAL FORM OF THE SALTS 4- (3-CHLORO-4- (CYCLOPROPYLAMINOCARBONYL) AMINO-PHENOXY) -7-METHOXY-6-HINOLINKARBOXAMIDE OR ITS SOLVATES AND THE PROCESS FOR THEIR PRODUCTION
WO2006030826A1 (ja) * 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
CA2606719C (en) * 2005-06-23 2010-08-10 Eisai R & D Management Co., Ltd. Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550483B2 (en) * 2005-06-23 2009-06-23 Eisai R&D Management Co., Ltd. Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same
US20090304694A1 (en) * 2006-01-27 2009-12-10 Amgen Inc. Ang2 and Vegf Inhibitor Combinations
US20110158983A1 (en) * 2008-03-05 2011-06-30 Newell Bascomb Compositions and methods for mucositis and oncology therapies

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9504746B2 (en) 2004-09-17 2016-11-29 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide
US20080214604A1 (en) * 2004-09-17 2008-09-04 Hisao Furitsu Medicinal Composition
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
US8969344B2 (en) 2005-08-02 2015-03-03 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
US20100092490A1 (en) * 2005-08-02 2010-04-15 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
US20080214557A1 (en) * 2005-09-01 2008-09-04 Eisai R&D Management Co., Ltd. Method for preparation of pharmaceutical composition having improved disintegratability and pharmaceutical composition manufactured by same method
US8815241B2 (en) 2005-11-07 2014-08-26 Eisai R&D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
US20110207756A1 (en) * 2006-05-18 2011-08-25 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
US9006256B2 (en) 2006-05-18 2015-04-14 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US20090264464A1 (en) * 2006-08-28 2009-10-22 Eisai R & D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
US20100048620A1 (en) * 2007-01-29 2010-02-25 Yuji Yamamoto Composition for treatment of undifferentiated gastric cancer
US20100239688A1 (en) * 2007-11-09 2010-09-23 Yuji Yamamoto Combination of anti-angiogenic substance and anti-tumor platinum complex
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US11598776B2 (en) 2011-06-03 2023-03-07 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
US11186547B2 (en) 2014-08-28 2021-11-30 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US10259791B2 (en) 2014-08-28 2019-04-16 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US10407393B2 (en) 2014-08-28 2019-09-10 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US10822307B2 (en) 2014-08-28 2020-11-03 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
EP3263106B1 (en) 2015-02-25 2023-10-25 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
WO2016136745A1 (ja) 2015-02-25 2016-09-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
EP3263106A4 (en) * 2015-02-25 2018-08-29 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
AU2016224583B2 (en) * 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
US11090386B2 (en) 2015-02-25 2021-08-17 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
US11547705B2 (en) 2015-03-04 2023-01-10 Merck Sharp & Dohme Llc Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer
US12083112B2 (en) 2015-03-04 2024-09-10 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
EP3606511B1 (en) 2017-04-04 2022-04-20 Synthon B.V. Pharmaceutical composition comprising lenvatinib mesylate
EP3384901A1 (en) * 2017-04-04 2018-10-10 Synthon B.V. Pharmaceutical composition comprising lenvatinib mesylate
WO2018185175A1 (en) * 2017-04-04 2018-10-11 Synthon B.V. Pharmaceutical composition comprising lenvatinib mesylate
US11911509B2 (en) 2017-04-04 2024-02-27 Synthon B.V. Pharmaceutical composition comprising Lenvatinib mesylate
CN110404079A (zh) * 2018-04-27 2019-11-05 北京睿创康泰医药研究院有限公司 一种不含碳酸盐、低基因毒性杂质含量的喹啉衍生物或其盐的药物组合物

Also Published As

Publication number Publication date
KR101496395B1 (ko) 2015-02-26
BR112012003592A2 (pt) 2016-03-15
AU2010285740A1 (en) 2011-12-15
CA2771403A1 (en) 2011-02-24
EP2468281A1 (en) 2012-06-27
SI2468281T1 (sl) 2016-05-31
PE20121030A1 (es) 2012-08-18
TH121482A (th) 2013-02-28
RU2548673C2 (ru) 2015-04-20
NZ598291A (en) 2013-02-22
DK2468281T3 (en) 2016-03-21
CA2771403C (en) 2015-02-24
CN102470133A (zh) 2012-05-23
HUE026957T2 (en) 2016-07-28
SMT201600077B (it) 2016-04-29
MX2012002011A (es) 2012-03-26
AU2010285740C1 (en) 2016-03-17
CO6440512A2 (es) 2012-05-15
UA105671C2 (uk) 2014-06-10
IL217197A0 (en) 2012-02-29
ES2564797T3 (es) 2016-03-29
JP5048871B2 (ja) 2012-10-17
RS54686B1 (en) 2016-08-31
BR112012003592B1 (pt) 2020-11-03
AU2010285740B2 (en) 2014-12-04
CY1117481T1 (el) 2017-04-26
WO2011021597A1 (ja) 2011-02-24
CN102470133B (zh) 2013-08-28
EP2468281A4 (en) 2013-01-23
SG178009A1 (en) 2012-03-29
US20210228722A1 (en) 2021-07-29
MY162940A (en) 2017-07-31
HK1169599A1 (zh) 2013-02-01
US20130296365A1 (en) 2013-11-07
BR112012003592B8 (pt) 2021-05-25
RU2548673C3 (ru) 2018-07-20
JPWO2011021597A1 (ja) 2013-01-24
KR20120055559A (ko) 2012-05-31
ME02359B (me) 2016-06-20
MX344927B (es) 2017-01-11
PL2468281T3 (pl) 2016-06-30
HRP20160283T1 (hr) 2016-05-06
HK1167607A1 (en) 2012-12-07
MA33581B1 (fr) 2012-09-01
IL217197A (en) 2016-08-31
RU2012103471A (ru) 2013-09-27
CL2012000412A1 (es) 2012-08-31
EP2468281B1 (en) 2016-01-27
ZA201108697B (en) 2012-07-25

Similar Documents

Publication Publication Date Title
US20210228722A1 (en) Quinoline derivative-containing pharmaceutical composition
TWI540128B (zh) 醫藥組合物
EP2815752B1 (en) Oral pharmaceutical composition
KR102517765B1 (ko) 로수바스타틴 및 에제티미브를 포함하는 제약 조성물 및 그의 제조 방법
EP4147689A1 (en) Lenvatinib formulation
EP3860606B1 (en) Pharmaceutical composition comprising lenvatinib esylate or tosylate
WO2017006855A1 (ja) 安定な経口投与用医薬組成物
JP2020518611A (ja) 水溶解度及びバイオアベイラビリティが改善された組成物
CN110404079B (zh) 一种不含碳酸盐、低基因毒性杂质含量的喹啉衍生物或其盐的药物组合物
KR102206104B1 (ko) 실로도신을 포함하는 과립물, 및 이를 포함하는 약학적 조성물 및 제형
US20070155780A1 (en) Stabilized composition containing 4-amino-5-chloro-n-[(1r, 3r, 5s)-8-methyl-8-azabicyclo[3.2.1]oct-3-y1]-2-[1-methylbut-2-ynyloxy]benzamide
CA2873961C (en) Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
JP2005112825A (ja) 胃内浮遊性固形製剤
TWI501950B (zh) 含喹啉衍生物的藥學組成物
EP2839835B1 (en) Encapsulated formulation
KR20220088362A (ko) 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민을 포함하는 신규한 경구투여용 제제
SA112330839B1 (ar) تركيب صيدلي وطريقة لتحضيره
CN118159274A (zh) 糖浆剂
JP2011063567A (ja) 保存安定性の向上した錠剤
WO2015063669A1 (en) Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: EISAI R&D MANAGEMENT CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BANDO, MASASHI;REEL/FRAME:027318/0169

Effective date: 20111101

STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION